Literature DB >> 30089301

Short-Term Microbiota Manipulation and Forearm Substrate Metabolism in Obese Men: A Randomized, Double-Blind, Placebo-Controlled Trial.

Dorien Reijnders1, Gijs H Goossens, Gerben D A Hermes, Hauke Smidt, Erwin G Zoetendal, Ellen E Blaak.   

Abstract

OBJECTIVE: To investigate the impact of gut microbiota manipulation on fasting and postprandial skeletal muscle metabolism in humans.
METHODS: 40 obese, insulin-resistant males were randomized to amoxicillin (broad-spectrum antibiotic), vancomycin (narrow-spectrum antibiotic), or placebo (7 days, 1,500 mg/day). Before and after treatment, forearm blood flow and metabolite fluxes across forearm muscle were measured under fasting and postprandial (high-fat mixed-meal) conditions.
RESULTS: Vancomycin decreased bacterial diversity, reduced the abundance of Gram-positive Firmicutes, and increased the abundance of Gram-negative Proteobacteria, whereas amoxicillin did not affect microbial composition. Neither vancomycin nor amoxicillin treatment affected fasting and postprandial plasma glucose, free fatty acid (FFA), triacylglycerol (TAG), glycerol, lactate, and insulin concentrations or forearm blood flow. Fasting and postprandial net forearm muscle glucose uptake and the release of lactate were not significantly altered by antibiotic treatment as compared to placebo. Finally, antibiotic treatment did not change fasting and postprandial glycerol, FFA, and TAG fluxes across forearm muscle.
CONCLUSION: The present study demonstrates that short-term antibiotic treatment has no effects on fasting and postprandial forearm substrate metabolism and blood flow in obese men with impaired glucose metabolism. These data suggest that short-term strategies targeting the gut microbiota to improve metabolic health may not be effective in obese humans.
© 2018 The Author(s) Published by S. Karger GmbH, Freiburg.

Entities:  

Keywords:  Antibiotics; Insulin resistance; Microbiota; Obesity; Skeletal muscle

Mesh:

Substances:

Year:  2018        PMID: 30089301      PMCID: PMC6189533          DOI: 10.1159/000492114

Source DB:  PubMed          Journal:  Obes Facts        ISSN: 1662-4025            Impact factor:   3.942


  33 in total

1.  Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Dorien Reijnders; Gijs H Goossens; Gerben D A Hermes; Evelien P J G Neis; Christina M van der Beek; Jasper Most; Jens J Holst; Kaatje Lenaerts; Ruud S Kootte; Max Nieuwdorp; Albert K Groen; Steven W M Olde Damink; Mark V Boekschoten; Hauke Smidt; Erwin G Zoetendal; Cornelis H C Dejong; Ellen E Blaak
Journal:  Cell Metab       Date:  2016-07-12       Impact factor: 27.287

2.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

3.  Skeletal muscle fatty acid handling in insulin resistant men.

Authors:  Anneke M J van Hees; Anneke Jans; Gabby B Hul; Helen M Roche; Wim H M Saris; Ellen E Blaak
Journal:  Obesity (Silver Spring)       Date:  2011-02-17       Impact factor: 5.002

4.  Vancomycin treatment of infective endocarditis is linked with recently acquired obesity.

Authors:  Franck Thuny; Hervé Richet; Jean-Paul Casalta; Emmanouil Angelakis; Gilbert Habib; Didier Raoult
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

5.  Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids.

Authors:  Hongfei Ge; Xiaofan Li; Jennifer Weiszmann; Ping Wang; Helene Baribault; Jin-Long Chen; Hui Tian; Yang Li
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

6.  Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans.

Authors:  R V Farese; T J Yost; R H Eckel
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

7.  Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.

Authors:  Weidong Chai; Zhenhua Dong; Nasui Wang; Wenhui Wang; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

8.  Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment.

Authors:  M Million; F Thuny; E Angelakis; J-P Casalta; R Giorgi; G Habib; D Raoult
Journal:  Nutr Diabetes       Date:  2013-09-09       Impact factor: 5.097

9.  Gut microbiota can transfer fiber characteristics and lipid metabolic profiles of skeletal muscle from pigs to germ-free mice.

Authors:  Honglin Yan; Hui Diao; Yi Xiao; Wenxia Li; Bing Yu; Jun He; Jie Yu; Ping Zheng; Xiangbing Mao; Yuheng Luo; Benhua Zeng; Hong Wei; Daiwen Chen
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

10.  Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism.

Authors:  Kristian H Mikkelsen; Morten Frost; Martin I Bahl; Tine R Licht; Ulrich S Jensen; Jacob Rosenberg; Oluf Pedersen; Torben Hansen; Jens F Rehfeld; Jens J Holst; Tina Vilsbøll; Filip K Knop
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

View more
  3 in total

Review 1.  The Role of Glucagon-Like Peptide-1 in Energy Homeostasis.

Authors:  Marzieh Salehi; Jonathan Q Purnell
Journal:  Metab Syndr Relat Disord       Date:  2019-02-05       Impact factor: 1.894

Review 2.  Role of the Gut Microbiome in Skeletal Muscle Physiology and Pathophysiology.

Authors:  Camille Lefevre; Laure B Bindels
Journal:  Curr Osteoporos Rep       Date:  2022-09-19       Impact factor: 5.163

3.  The impact of antibiotics on the metabolic status of obese adults without bacterial infection: a systematic review and meta-analysis.

Authors:  Naofumi Yoshida; Yoshihiro Saito; Yasushi Tsujimoto; Shunsuke Taito; Masahiro Banno; Yuki Kataoka; Tomoya Yamashita; Ken-Ichi Hirata
Journal:  Ann Transl Med       Date:  2020-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.